A Phase 2 interventional study of Entrectinib and Inavolisib in Advanced Unresectable or Metastatic Solid Malignancy, sponsored by Genentech, Inc.. Completed at 38 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-08.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase II, multicenter, non-randomized, open-label, multi-arm study designed to evaluate the safety and efficacy of targeted therapies as single agents or in rational, specified combinations in participants with advanced unresectable or metastatic solid tumors determined to harbor specific biomarkers.
Patients will be enrolled based on local testing performed at a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited diagnostic laboratory. The multi-arm structure of the MyTACTIC study allows patients with solid tumors to be treated with a drug or drug regimen tailored to their biomarker identified at screening.
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
First submitted after Genentech, Inc. became part of Hoffmann-La Roche.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this treatment arm must have a positive tumor biomarker result for ROS1 gene fusion.
Drug: Entrectinib
Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.
Drug: Inavolisib
Participants in this treatment arm must have a positive tumor biomarker result for ALK rearrangement tumors.
Drug: Alectinib
Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.
Drug: Ipatasertib
Participants in this treatment arm must have a positive tumor biomarker result for either tumor mutational burden (TMB) high or microsatellite instability (MSI) high/deficient mismatch repair (dMMR).
Drug: Atezolizumab · Drug: Investigator's Choice of Chemotherapy
Participants in this treatment arm must have a positive tumor biomarker result for human epidermal growth factor receptor 2 (HER2) mutations or amplification without known TMB high or MSI high/dMMR.
Drug: Atezolizumab · Drug: Trastuzumab Emtansine
Participants in this treatment arm must have a positive tumor biomarker result for HER2 mutation or amplification without known TMB high or MSI high/dMMR.
Drug: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
Participants in this treatment arm must have a positive tumor biomarker result for HER2 mutation or amplification without known TMB high or MSI high/dMMR.
Drug: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf · Drug: Investigator's Choice of Chemotherapy
Participants in this treatment arm must have a positive tumor biomarker result for HER2 mutation or amplification without known TMB high or MSI high/dMMR.
Drug: Trastuzumab Emtansine · Drug: Tucatinib
Participants in this treatment arm must have positive tumor biomarker results for HER2 mutation or amplification and TMB high or MSI high/dMMR.
Drug: Atezolizumab · Drug: Trastuzumab Emtansine
Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.
Drug: Ipatasertib · Drug: Atezolizumab
Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.
Drug: Ipatasertib · Drug: Atezolizumab
Participants in this treatment arm must have a positive tumor biomarker results for PI3KCA activating mutations and either AKT1/2/3 activating mutation or PTEN loss/loss of function.
Drug: Ipatasertib · Drug: Paclitaxel
Participants in this treatment arm must have a positive tumor biomarker result for either TMB high or MSI high/dMMR.
Drug: Atezolizumab · Drug: Tiragolumab
Participants in this treatment arm must have a positive tumor biomarker result for RET fusion.
Drug: Pralsetinib
Entrectinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 600 milligrams (mg) per day once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
Also known as: Rozlytrek™, RG6268, RO7102122
Inavolisib will be self-administered by participants orally at home (except on clinic days) at the same time each day, on a starting dose of 9 mg/day QD until disease progression, intolerable toxicity, or consent withdrawal.
Also known as: GDC-0077, RG6114, RO7113755
Alectinib will be self-administered by participants orally at home (except on clinic days), at the same times each day, on a starting dose of 600 mg twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal.
Also known as: Alecensa®, RG7853, RO5424802
Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.
Also known as: GDC-0068, RG7440, RO5532961
Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
Also known as: Tecentriq®, RG7446, RO5541267
Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
Also known as: Kadcyla®, RG3502, RO5304020
Drug page: Pertuzumab/Trastuzumab/Hyaluronidase-zzxf
PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.
Also known as: PHESGO™, PH FDC SC, Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously, RG6264, RO7198574
Tucatinib 300 mg will be administered orally BID continuously starting from Cycle 1 Day 1 onwards.
Also known as: Tukysa™
Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.
The dose of paclitaxel is 80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. The paclitaxel infusion will be delivered over at least 60 minutes for each dose per institutional guidelines and administered after the oral dose of ipatasertib.
Following the administration of atezolizumab and an observation period, participants will receive 600 mg tiragolumab at a fixed dose administered by IV infusion on Day 1 of each 21-day cycle.
Also known as: RG6058, RO7092284, MTIG7192A
Pralsetinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg/day (four 100-mg capsules per day) once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
Also known as: GAVRETO™, RG6396, RO7499790
This study also gives Trastuzumab, Pertuzumab. No intervention listed here names it: that was found by reading the record.
Confirmed Objective Response Rate (ORR) Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria for Primary Central Nervous System (CNS) Tumors
Confirmed objective response rate (cORR)=percentage of participants with best response as complete response (CR) or partial response (PR) for measurable disease \& CR for non-measurable disease. Confirmation=CR/PR on 2 consecutive visits ≥4 weeks apart for 3-week cycles \& ≥6 weeks apart for 4-week cycles. Per RECIST, CR=disappearance of all target lesions. PR= ≥30% decrease in sum of diameters of target lesions, in absence of CR. Per RANO, CR=complete disappearance of all measurable \& non-measurable disease for ≥4 weeks; no new lesions/abnormality on T2/FLAIR imaging; stable/improved non-enhancing lesions; participants must be off corticosteroids or on physiological doses; clinical status stable/improved. PR= ≥50% decrease in the sum of products of perpendicular diameters of measurable enhancing lesions on T2/FLAIR imaging for ≥4 weeks; no progression of non-measurable T1 disease; stable/improved non-enhancing lesions; corticosteroid dose ≤ baseline; clinical status stable/improved.
Time frame: Up to 32 months
Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
PFS=time from start of treatment to the first occurrence of disease progression (PD) or death from any cause, whichever occurs first, per RECIST v1.1, or RANO. Per RECIST, PD=≥20% increase in sum of diameters of lesions, using the smallest sum during the study as reference, including baseline (BL). Per RANO, PD= ≥25% increase in sum of products of perpendicular diameters of enhancing lesions compared to smallest tumor measurement at BL/best response, on stable/increasing corticosteroids (CS) dose; Significant/ ≥25% increase of T2/FLAIR non-enhancing lesion on stable/increasing CS dose compared to BL/best response after therapy start; Presence of new lesions/increase of enhancement; Clear progression of non-measurable disease; Definite clinical deterioration only due to tumor/decrease in CS dose; Failure to return for evaluation due to death/deterioration. Kaplan-Meier methodology was used to estimate PFS; patients without an event were censored on the last available assessment day.
Time frame: Time from start of treatment to the first occurrence of disease progression or death from any cause (Up to 32 months)
Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
DOR was defined as the time from the date of the first confirmed complete response (CR) or partial response (PR) to disease progression (PD) or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1 or RANO. CR \& PR were defined per RECIST or RANO as outlined in the description for the cORR outcome measure (OM). PD was defined per RECIST or RANO as outlined in the description for the PFS OM. Kaplan-Meier methodology was used to estimate the median DOR. The 95% confidence intervals for the median DOR were computed by the method of Brookmeyer and Crowley. Participants who did not experience death or PD were censored on the day of the last available assessment.
Time frame: Time from the date of the first confirmed CR/PR to PD or death from any cause (Up to 32 months)
PFS Rate at Month 3, 6, 9, and 12 as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
The PFS rates were calculated using the Kaplan-Meier (KM) method to estimate the percent survival probability of participants (i.e., PFS event-free: did not experience PD or death from any cause) in each treatment arm at landmark timepoints. The 95% confidence intervals for each PFS rate were computed by the method of Greenwood. PFS was defined as the time from the start of study treatment to the first occurrence of PD or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1 or RANO. PD was defined per RECIST or RANO as outlined in the description for the PFS OM. Participants who did not experience death or PD were censored on the day of the last available assessment. The number analyzed per landmark timepoint actually represents the number of participants who remained at risk of experiencing a PFS event at that timepoint. Percentages are rounded off to the nearest decimal point.
Time frame: At Months 3, 6, 9 and 12
Percentage of Participants With Disease Control, as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
Disease control rate was defined as the percentage of participants whose best response was confirmed CR, confirmed PR, or a response of CR, PR, stable disease (SD), or non-CR/non-PD for a minimum of 98 days for 28-day cycle arms or 70 days for 21-day cycle arms after the first treatment date. CR \& PR were defined per RECIST/RANO as outlined in the description for the cORR OM. SD per RECIST: Neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. SD per RANO: Participant does not qualify for CR, PR, or minor response or PD; Stable non-enhancing (T2/FLAIR) lesions or abnormalities on same or lower dose of corticosteroids compared to baseline; No new lesions or new T2 or FLAIR abnormalities apart from those consistent with radiation effect, \& no new or increased enhancement; Participants on a should be corticosteroid dose that is not greater than dose at baseline scan \& is stable or improved clinically; Clinical status, stable/improved.
Time frame: Up to 32 months
Number of Participants With at Least One Adverse Event (AE) and Severity of AEs Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)
An AE is an untoward medical occurrence in participant administered a pharmaceutical product \& regardless of causal relationship with the product. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to it. AEs were graded for severity according to NCI CTCAE v5.0. Grade 1= Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated; Grade 2=Moderate; minimal, local or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living; Grade 3 = Severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living; Grade 4= Life-threatening consequences/urgent intervention indicated; Grade 5= Death related to adverse event.
Time frame: From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
A total of 252 participants with advanced unresectable or metastatic solid tumors with positive biomarker result took part in the study across 38 investigative sites in the United States.
| Milestone | Arm B: Inavolisib (GDC-0077) | Arm C: Alectinib | Arm D: Ipatasertib | Arm E: Atezolizumab + Chemotherapy | Arm F: Trastuzumab Emtansine + Atezolizumab | Arm G: PH FDC SC | Arm H: PH FDC SC + Chemotherapy | Arm I: Trastuzumab Emtansine + Tucatinib | Arm J: Trastuzumab Emtansine + Atezolizumab | Arm K: Ipatasertib + Atezolizumab | Arm L: Ipatasertib + Atezolizumab | Arm M: Ipatasertib + Paclitaxel | Arm N: Atezolizumab + Tiragolumab | Arm O: Pralsetinib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 26 | 5 | 26 | 25 | 25 | 13 | 8 | 23 | 19 | 28 | 25 | 3 | 23 | 3 |
| Completed | 2 | 3 | 5 | 4 | 5 | 4 | 0 | 5 | 3 | 4 | 5 | 1 | 6 | 1 |
| Not completed | 24 | 2 | 21 | 21 | 20 | 9 | 8 | 18 | 16 | 24 | 20 | 2 | 17 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Death | 17 | 1 | 14 | 14 | 13 | 6 | 7 | 12 | 15 | 20 | 8 | 2 | 10 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 | 2 | 0 | 1 | 1 | 1 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 4 | 1 | 5 | 4 | 3 | 3 | 0 | 5 | 0 | 2 | 8 | 0 | 1 | 1 |
Confirmed objective response rate (cORR)=percentage of participants with best response as complete response (CR) or partial response (PR) for measurable disease \& CR for non-measurable disease. Confirmation=CR/PR on 2 consecutive visits ≥4 weeks apart for 3-week cycles \& ≥6 weeks apart for 4-week cycles. Per RECIST, CR=disappearance of all target lesions. PR= ≥30% decrease in sum of diameters of target lesions, in absence of CR. Per RANO, CR=complete disappearance of all measurable \& non-measurable disease for ≥4 weeks; no new lesions/abnormality on T2/FLAIR imaging; stable/improved non-enhancing lesions; participants must be off corticosteroids or on physiological doses; clinical status stable/improved. PR= ≥50% decrease in the sum of products of perpendicular diameters of measurable enhancing lesions on T2/FLAIR imaging for ≥4 weeks; no progression of non-measurable T1 disease; stable/improved non-enhancing lesions; corticosteroid dose ≤ baseline; clinical status stable/improved.
| percentage of participants | Arm B: Inavolisib (GDC-0077) | Arm C: Alectinib | Arm D: Ipatasertib | Arm E: Atezolizumab + Chemotherapy | Arm F: Trastuzumab Emtansine + Atezolizumab | Arm G: PH FDC SC | Arm H: PH FDC SC + Chemotherapy | Arm I: Trastuzumab Emtansine + Tucatinib | Arm J: Trastuzumab Emtansine + Atezolizumab | Arm K: Ipatasertib + Atezolizumab | Arm L: Ipatasertib + Atezolizumab | Arm M: Ipatasertib + Paclitaxel | Arm N: Atezolizumab + Tiragolumab | Arm O: Pralsetinib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Confirmed Objective Response Rate (ORR) Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria for Primary Central Nervous System (CNS) Tumors | 11.5 (2.4 to 30.2) | 20.0 (0.5 to 71.6) | 11.5 (2.4 to 30.2) | 28.0 (12.1 to 49.4) | 12.0 (2.5 to 31.2) | 0.0 (0.0 to 24.7) | 0.0 (0.0 to 36.9) | 13.0 (2.8 to 33.6) | 0.0 (0.0 to 17.6) | 0.0 (0.0 to 12.3) | 0.0 (0.0 to 13.7) | 66.7 (9.4 to 99.2) | 21.7 (7.5 to 43.7) | 33.3 (0.8 to 90.6) |
PFS=time from start of treatment to the first occurrence of disease progression (PD) or death from any cause, whichever occurs first, per RECIST v1.1, or RANO. Per RECIST, PD=≥20% increase in sum of diameters of lesions, using the smallest sum during the study as reference, including baseline (BL). Per RANO, PD= ≥25% increase in sum of products of perpendicular diameters of enhancing lesions compared to smallest tumor measurement at BL/best response, on stable/increasing corticosteroids (CS) dose; Significant/ ≥25% increase of T2/FLAIR non-enhancing lesion on stable/increasing CS dose compared to BL/best response after therapy start; Presence of new lesions/increase of enhancement; Clear progression of non-measurable disease; Definite clinical deterioration only due to tumor/decrease in CS dose; Failure to return for evaluation due to death/deterioration. Kaplan-Meier methodology was used to estimate PFS; patients without an event were censored on the last available assessment day.
| months | Arm B: Inavolisib (GDC-0077) | Arm C: Alectinib | Arm D: Ipatasertib | Arm E: Atezolizumab + Chemotherapy | Arm F: Trastuzumab Emtansine + Atezolizumab | Arm G: PH FDC SC | Arm H: PH FDC SC + Chemotherapy | Arm I: Trastuzumab Emtansine + Tucatinib | Arm J: Trastuzumab Emtansine + Atezolizumab | Arm K: Ipatasertib + Atezolizumab | Arm L: Ipatasertib + Atezolizumab | Arm M: Ipatasertib + Paclitaxel | Arm N: Atezolizumab + Tiragolumab | Arm O: Pralsetinib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1 or RANO Criteria | 4.24 (1.84 to 8.08) | 4.98 (1.54 to NA) | 3.48 (1.87 to 6.47) | 3.94 (2.17 to 8.38) | 4.73 (2.07 to 10.22) | 2.46 (1.77 to 5.16) | 3.02 (1.54 to 5.52) | 2.69 (1.94 to 6.18) | 1.87 (1.71 to 2.20) | 2.10 (1.64 to 3.48) | 3.61 (2.33 to 6.34) | 5.98 (1.28 to NA) | 4.76 (1.87 to 16.43) | 7.10 (1.84 to NA) |
DOR was defined as the time from the date of the first confirmed complete response (CR) or partial response (PR) to disease progression (PD) or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1 or RANO. CR \& PR were defined per RECIST or RANO as outlined in the description for the cORR outcome measure (OM). PD was defined per RECIST or RANO as outlined in the description for the PFS OM. Kaplan-Meier methodology was used to estimate the median DOR. The 95% confidence intervals for the median DOR were computed by the method of Brookmeyer and Crowley. Participants who did not experience death or PD were censored on the day of the last available assessment.
| months | Arm B: Inavolisib (GDC-0077) | Arm C: Alectinib | Arm D: Ipatasertib | Arm E: Atezolizumab + Chemotherapy | Arm F: Trastuzumab Emtansine + Atezolizumab | Arm G: PH FDC SC | Arm H: PH FDC SC + Chemotherapy | Arm I: Trastuzumab Emtansine + Tucatinib | Arm J: Trastuzumab Emtansine + Atezolizumab | Arm K: Ipatasertib + Atezolizumab | Arm L: Ipatasertib + Atezolizumab | Arm M: Ipatasertib + Paclitaxel | Arm N: Atezolizumab + Tiragolumab | Arm O: Pralsetinib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1 or RANO Criteria | 5.6 (5.3 to NA) | 6.5 (NA to NA) | 5.5 (3.7 to NA) | NA (7.4 to NA) | 20.0 (NA to NA) | — | — | 7.6 (3.7 to NA) | — | — | — | 5.5 (4.0 to NA) | NA (3.6 to NA) | NA (NA to NA) |
The PFS rates were calculated using the Kaplan-Meier (KM) method to estimate the percent survival probability of participants (i.e., PFS event-free: did not experience PD or death from any cause) in each treatment arm at landmark timepoints. The 95% confidence intervals for each PFS rate were computed by the method of Greenwood. PFS was defined as the time from the start of study treatment to the first occurrence of PD or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1 or RANO. PD was defined per RECIST or RANO as outlined in the description for the PFS OM. Participants who did not experience death or PD were censored on the day of the last available assessment. The number analyzed per landmark timepoint actually represents the number of participants who remained at risk of experiencing a PFS event at that timepoint. Percentages are rounded off to the nearest decimal point.
| percent probability | Arm B: Inavolisib (GDC-0077) | Arm C: Alectinib | Arm D: Ipatasertib | Arm E: Atezolizumab + Chemotherapy | Arm F: Trastuzumab Emtansine + Atezolizumab | Arm G: PH FDC SC | Arm H: PH FDC SC + Chemotherapy | Arm I: Trastuzumab Emtansine + Tucatinib | Arm J: Trastuzumab Emtansine + Atezolizumab | Arm K: Ipatasertib + Atezolizumab | Arm L: Ipatasertib + Atezolizumab | Arm M: Ipatasertib + Paclitaxel | Arm N: Atezolizumab + Tiragolumab | Arm O: Pralsetinib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 months | 57.69 (38.7 to 76.68) | 50.00 (1.00 to 99.00) | 52.00 (32.42 to 71.58) | 52.17 (31.76 to 72.59) | 64.00 (45.18 to 82.82) | 41.03 (12.19 to 69.86) | 50.00 (15.35 to 84.65) | 48.13 (26.77 to 69.49) | 26.32 (6.52 to 46.12) | 35.56 (17.13 to 53.98) | 65.22 (45.75 to 84.68) | 66.67 (13.32 to 100.00) | 59.09 (38.55 to 79.64) | 66.67 (13.32 to 100.00) |
| 6 months | 37.09 (18.15 to 56.03) | 50.00 (1.00 to 99.00) | 36.00 (17.18 to 54.82) | 33.20 (13.48 to 52.92) | 44.00 (24.54 to 63.46) | 20.51 (0.0 to 45.25) | 12.50 (0.00 to 35.42) | 33.69 (13.43 to 53.95) | 10.53 (0.00 to 24.33) | 11.85 (0.00 to 24.41) | 33.82 (14.13 to 53.51) | 33.33 (0.00 to 86.68) | 40.91 (20.36 to 61.45) | 66.67 (13.32 to 100.00) |
| 9 months | 20.60 (4.61 to 36.59) | 25.00 (0.00 to 67.43) | 9.00 (0.00 to 20.78) | 28.46 (9.49 to 47.42) | 32.00 (13.71 to 50.29) | 10.26 (0.00 to 29.10) | — | 19.25 (2.32 to 36.18) | 10.53 (0.00 to 24.33) | 3.95 (0.00 to 11.53) | 24.15 (6.10 to 42.21) | — | 36.36 (16.26 to 56.46) | — |
| 12 months | 16.48 (1.79 to 31.17) | — | 4.50 (0.00 to 13.08) | 18.97 (2.39 to 35.56) | 23.33 (6.46 to 40.21) | — | — | 9.63 (0.00 to 22.30) | — | — | 14.49 (0.00 to 29.49) | — | 36.36 (16.26 to 56.46) | — |
Disease control rate was defined as the percentage of participants whose best response was confirmed CR, confirmed PR, or a response of CR, PR, stable disease (SD), or non-CR/non-PD for a minimum of 98 days for 28-day cycle arms or 70 days for 21-day cycle arms after the first treatment date. CR \& PR were defined per RECIST/RANO as outlined in the description for the cORR OM. SD per RECIST: Neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. SD per RANO: Participant does not qualify for CR, PR, or minor response or PD; Stable non-enhancing (T2/FLAIR) lesions or abnormalities on same or lower dose of corticosteroids compared to baseline; No new lesions or new T2 or FLAIR abnormalities apart from those consistent with radiation effect, \& no new or increased enhancement; Participants on a should be corticosteroid dose that is not greater than dose at baseline scan \& is stable or improved clinically; Clinical status, stable/improved.
| percentage of participants | Arm B: Inavolisib (GDC-0077) | Arm C: Alectinib | Arm D: Ipatasertib | Arm E: Atezolizumab + Chemotherapy | Arm F: Trastuzumab Emtansine + Atezolizumab | Arm G: PH FDC SC | Arm H: PH FDC SC + Chemotherapy | Arm I: Trastuzumab Emtansine + Tucatinib | Arm J: Trastuzumab Emtansine + Atezolizumab | Arm K: Ipatasertib + Atezolizumab | Arm L: Ipatasertib + Atezolizumab | Arm M: Ipatasertib + Paclitaxel | Arm N: Atezolizumab + Tiragolumab | Arm O: Pralsetinib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Disease Control, as Determined by the Investigator According to RECIST v1.1 or RANO Criteria | 57.7 (36.9 to 76.6) | 40.0 (5.3 to 85.3) | 34.6 (17.2 to 55.7) | 32.0 (14.9 to 53.5) | 52.0 (31.3 to 72.2) | 23.1 (5.0 to 53.8) | 37.5 (8.5 to 75.5) | 26.1 (10.2 to 48.4) | 15.8 (3.4 to 39.6) | 10.7 (2.3 to 28.2) | 32.0 (14.9 to 53.5) | 66.7 (9.4 to 99.2) | 47.8 (26.8 to 69.4) | 66.7 (9.4 to 99.2) |
An AE is an untoward medical occurrence in participant administered a pharmaceutical product \& regardless of causal relationship with the product. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to it. AEs were graded for severity according to NCI CTCAE v5.0. Grade 1= Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated; Grade 2=Moderate; minimal, local or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living; Grade 3 = Severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living; Grade 4= Life-threatening consequences/urgent intervention indicated; Grade 5= Death related to adverse event.
| Participants | Arm B: Inavolisib (GDC-0077) | Arm C: Alectinib | Arm D: Ipatasertib | Arm E: Atezolizumab + Chemotherapy | Arm F: Trastuzumab Emtansine + Atezolizumab | Arm G: PH FDC SC | Arm H: PH FDC SC + Chemotherapy | Arm I: Trastuzumab Emtansine + Tucatinib | Arm J: Trastuzumab Emtansine + Atezolizumab | Arm K: Ipatasertib + Atezolizumab | Arm L: Ipatasertib + Atezolizumab | Arm M: Ipatasertib + Paclitaxel | Arm N: Atezolizumab + Tiragolumab | Arm O: Pralsetinib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any Adverse Event (AE), Any Grade | 25 | 5 | 25 | 25 | 24 | 11 | 8 | 23 | 19 | 27 | 25 | 3 | 21 | 3 |
| Highest Severity: Grade 1 AEs | 3 | 0 | 1 | 0 | 3 | 3 | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 0 |
| Highest Severity: Grade 2 AEs | 14 | 2 | 14 | 9 | 10 | 6 | 3 | 11 | 7 | 7 | 11 | 0 | 11 | 0 |
| Highest Severity: Grade 3 AEs | 6 | 2 | 9 | 11 | 11 | 2 | 4 | 7 | 11 | 16 | 10 | 3 | 8 | 2 |
| Highest Severity: Grade 4 AEs | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 4 | 0 | 1 | 2 | 0 | 0 | 0 |
| Highest Severity: Grade 5 AEs | 2 | 0 | 0 | 4 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 1 |
Collected over From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm B: Inavolisib (GDC-0077) | 19/26 (73.1%) | 5/26 (19.2%) | 25/26 (96.2%) |
| Arm C: Alectinib | 1/5 (20%) | 2/5 (40%) | 5/5 (100%) |
| Arm D: Ipatasertib | 16/26 (61.5%) | 6/26 (23.1%) | 25/26 (96.2%) |
| Arm E: Atezolizumab + Chemotherapy | 16/25 (64%) | 11/25 (44%) | 25/25 (100%) |
| Arm F: Trastuzumab Emtansine + Atezolizumab | 16/25 (64%) | 9/25 (36%) | 23/25 (92%) |
| Arm G: PH FDC SC | 6/13 (46.2%) | 2/13 (15.4%) | 11/13 (84.6%) |
| Arm H: PH FDC SC + Chemotherapy | 8/8 (100%) | 2/8 (25%) | 8/8 (100%) |
| Arm I: Trastuzumab Emtansine + Tucatinib | 14/23 (60.9%) | 6/23 (26.1%) | 23/23 (100%) |
| Arm J: Trastuzumab Emtansine + Atezolizumab | 16/19 (84.2%) | 7/19 (36.8%) | 19/19 (100%) |
| Arm K: Ipatasertib + Atezolizumab | 22/28 (78.6%) | 10/28 (35.7%) | 26/28 (92.9%) |
| Arm L: Ipatasertib + Atezolizumab | 10/25 (40%) | 8/25 (32%) | 25/25 (100%) |
| Arm M: Ipatasertib + Paclitaxel | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Arm N: Atezolizumab + Tiragolumab | 10/23 (43.5%) | 6/23 (26.1%) | 21/23 (91.3%) |
| Arm O: Pralsetinib | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Event | Arm B: Inavolisib (GDC-0077) | Arm C: Alectinib | Arm D: Ipatasertib | Arm E: Atezolizumab + Chemotherapy | Arm F: Trastuzumab Emtansine + Atezolizumab | Arm G: PH FDC SC | Arm H: PH FDC SC + Chemotherapy | Arm I: Trastuzumab Emtansine + Tucatinib | Arm J: Trastuzumab Emtansine + Atezolizumab | Arm K: Ipatasertib + Atezolizumab | Arm L: Ipatasertib + Atezolizumab | Arm M: Ipatasertib + Paclitaxel | Arm N: Atezolizumab + Tiragolumab | Arm O: Pralsetinib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/26 | 0/5 | 0/26 | 0/25 | 0/25 | 0/13 | 0/8 | 2/23 | 0/19 | 0/28 | 0/25 | 0/3 | 0/23 | 1/3 |
| DiarrhoeaGastrointestinal disorders | 0/26 | 0/5 | 1/26 | 0/25 | 1/25 | 0/13 | 1/8 | 0/23 | 0/19 | 2/28 | 1/25 | 0/3 | 0/23 | 1/3 |
| Gastrointestinal fistulaGastrointestinal disorders | 0/26 | 0/5 | 0/26 | 0/25 | 0/25 | 0/13 | 0/8 | 0/23 | 0/19 | 0/28 | 0/25 | 1/3 | 0/23 | 0/3 |
| Rectal haemorrhageGastrointestinal disorders | 0/26 | 0/5 | 0/26 | 0/25 | 0/25 | 0/13 | 0/8 | 0/23 | 0/19 | 0/28 | 0/25 | 1/3 | 0/23 | 0/3 |
| Abdominal infectionInfections and infestations | 0/26 | 0/5 | 0/26 | 0/25 | 0/25 | 0/13 | 0/8 | 0/23 | 0/19 | 0/28 | 0/25 | 1/3 | 0/23 | 0/3 |
| Clostridium difficile infectionInfections and infestations | 0/26 | 0/5 | 0/26 | 0/25 | 0/25 | 0/13 | 0/8 | 0/23 | 0/19 | 0/28 | 1/25 | 0/3 | 0/23 | 1/3 |
| Colonic abscessInfections and infestations | 0/26 | 0/5 | 0/26 | 0/25 | 0/25 | 0/13 | 0/8 | 0/23 | 0/19 | 0/28 | 0/25 | 0/3 | 0/23 | 1/3 |
| SepsisInfections and infestations | 0/26 | 0/5 | 0/26 | 1/25 | 0/25 | 0/13 | 0/8 | 0/23 | 1/19 | 0/28 | 0/25 | 1/3 | 1/23 | 0/3 |
| Brain oedemaNervous system disorders | 0/26 | 0/5 | 0/26 | 0/25 | 0/25 | 0/13 | 0/8 | 0/23 | 0/19 | 0/28 | 0/25 | 0/3 | 0/23 | 1/3 |
| SeizureNervous system disorders | 0/26 | 0/5 | 0/26 | 0/25 | 0/25 | 0/13 | 0/8 | 0/23 | 0/19 | 0/28 | 0/25 | 0/3 | 1/23 | 1/3 |
| Event | Arm B: Inavolisib (GDC-0077) | Arm C: Alectinib | Arm D: Ipatasertib | Arm E: Atezolizumab + Chemotherapy | Arm F: Trastuzumab Emtansine + Atezolizumab | Arm G: PH FDC SC | Arm H: PH FDC SC + Chemotherapy | Arm I: Trastuzumab Emtansine + Tucatinib | Arm J: Trastuzumab Emtansine + Atezolizumab | Arm K: Ipatasertib + Atezolizumab | Arm L: Ipatasertib + Atezolizumab | Arm M: Ipatasertib + Paclitaxel | Arm N: Atezolizumab + Tiragolumab | Arm O: Pralsetinib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/26 | 1/5 | 2/26 | 5/25 | 5/25 | 2/13 | 0/8 | 5/23 | 1/19 | 3/28 | 1/25 | 3/3 | 6/23 | 2/3 |
| ConstipationGastrointestinal disorders | 4/26 | 1/5 | 4/26 | 4/25 | 6/25 | 1/13 | 2/8 | 4/23 | 1/19 | 3/28 | 1/25 | 3/3 | 7/23 | 1/3 |
| DiarrhoeaGastrointestinal disorders | 6/26 | 0/5 | 19/26 | 16/25 | 3/25 | 5/13 | 3/8 | 8/23 | 3/19 | 18/28 | 18/25 | 3/3 | 4/23 | 2/3 |
| NauseaGastrointestinal disorders | 7/26 | 2/5 | 13/26 | 8/25 | 6/25 | 2/13 | 1/8 | 11/23 | 6/19 | 13/28 | 11/25 | 3/3 | 10/23 | 1/3 |
| FatigueGeneral disorders | 9/26 | 1/5 | 5/26 | 13/25 | 13/25 | 4/13 | 1/8 | 12/23 | 8/19 | 9/28 | 12/25 | 3/3 | 6/23 | 1/3 |
| StomatitisGastrointestinal disorders | 5/26 | 0/5 | 1/26 | 3/25 | 4/25 | 1/13 | 0/8 | 3/23 | 4/19 | 4/28 | 1/25 | 2/3 | 1/23 | 0/3 |
| PyrexiaGeneral disorders | 1/26 | 0/5 | 0/26 | 2/25 | 3/25 | 1/13 | 0/8 | 2/23 | 4/19 | 2/28 | 1/25 | 1/3 | 1/23 | 2/3 |
| Alanine aminotransferase increasedInvestigations | 0/26 | 0/5 | 2/26 | 1/25 | 5/25 | 0/13 | 0/8 | 6/23 | 0/19 | 1/28 | 3/25 | 2/3 | 3/23 | 1/3 |
| Aspartate aminotransferase increasedInvestigations | 1/26 | 0/5 | 3/26 | 1/25 | 7/25 | 0/13 | 0/8 | 11/23 | 3/19 | 1/28 | 2/25 | 2/3 | 3/23 | 1/3 |
| DehydrationMetabolism and nutrition disorders | 1/26 | 0/5 | 5/26 | 8/25 | 4/25 | 1/13 | 0/8 | 3/23 | 5/19 | 6/28 | 9/25 | 2/3 | 6/23 | 0/3 |
Safety evaluable population included all participants who received at least one dose of the study drug.
| Age, Continuous(years) | Arm B: Inavolisib (GDC-0077) | Arm C: Alectinib | Arm D: Ipatasertib | Arm E: Atezolizumab + Chemotherapy | Arm F: Trastuzumab Emtansine + Atezolizumab | Arm G: PH FDC SC | Arm H: PH FDC SC + Chemotherapy | Arm I: Trastuzumab Emtansine + Tucatinib | Arm J: Trastuzumab Emtansine + Atezolizumab | Arm K: Ipatasertib + Atezolizumab | Arm L: Ipatasertib + Atezolizumab | Arm M: Ipatasertib + Paclitaxel | Arm N: Atezolizumab + Tiragolumab | Arm O: Pralsetinib | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 64.5 ± 11.5 | 62.6 ± 6.7 | 66.7 ± 10.0 | 66.0 ± 12.0 | 66.1 ± 12.9 | 63.8 ± 10.7 | 61.1 ± 12.8 | 64.2 ± 12.0 | 61.8 ± 10.7 | 60.3 ± 10.4 | 59.8 ± 11.4 | 57.7 ± 19.4 | 63.7 ± 11.0 | 71.3 ± 16.2 | 63.6 ± 11.4 |
| Sex: Female, Male(Participants) | Arm B: Inavolisib (GDC-0077) | Arm C: Alectinib | Arm D: Ipatasertib | Arm E: Atezolizumab + Chemotherapy | Arm F: Trastuzumab Emtansine + Atezolizumab | Arm G: PH FDC SC | Arm H: PH FDC SC + Chemotherapy | Arm I: Trastuzumab Emtansine + Tucatinib | Arm J: Trastuzumab Emtansine + Atezolizumab | Arm K: Ipatasertib + Atezolizumab | Arm L: Ipatasertib + Atezolizumab | Arm M: Ipatasertib + Paclitaxel | Arm N: Atezolizumab + Tiragolumab | Arm O: Pralsetinib | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 18 | 4 | 18 | 11 | 8 | 7 | 5 | 15 | 9 | 19 | 15 | 2 | 14 | 1 | 146 |
| Male | 8 | 1 | 8 | 14 | 17 | 6 | 3 | 8 | 10 | 9 | 10 | 1 | 9 | 2 | 106 |
| Ethnicity (NIH/OMB)(Participants) | Arm B: Inavolisib (GDC-0077) | Arm C: Alectinib | Arm D: Ipatasertib | Arm E: Atezolizumab + Chemotherapy | Arm F: Trastuzumab Emtansine + Atezolizumab | Arm G: PH FDC SC | Arm H: PH FDC SC + Chemotherapy | Arm I: Trastuzumab Emtansine + Tucatinib | Arm J: Trastuzumab Emtansine + Atezolizumab | Arm K: Ipatasertib + Atezolizumab | Arm L: Ipatasertib + Atezolizumab | Arm M: Ipatasertib + Paclitaxel | Arm N: Atezolizumab + Tiragolumab | Arm O: Pralsetinib | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 3 | 0 | 11 |
| Not Hispanic or Latino | 26 | 5 | 24 | 24 | 24 | 12 | 6 | 20 | 17 | 26 | 25 | 3 | 20 | 3 | 235 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 6 |
| Race (NIH/OMB)(Participants) | Arm B: Inavolisib (GDC-0077) | Arm C: Alectinib | Arm D: Ipatasertib | Arm E: Atezolizumab + Chemotherapy | Arm F: Trastuzumab Emtansine + Atezolizumab | Arm G: PH FDC SC | Arm H: PH FDC SC + Chemotherapy | Arm I: Trastuzumab Emtansine + Tucatinib | Arm J: Trastuzumab Emtansine + Atezolizumab | Arm K: Ipatasertib + Atezolizumab | Arm L: Ipatasertib + Atezolizumab | Arm M: Ipatasertib + Paclitaxel | Arm N: Atezolizumab + Tiragolumab | Arm O: Pralsetinib | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 0 | 2 | 0 | 0 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 4 | 0 | 4 | 1 | 2 | 1 | 3 | 2 | 0 | 0 | 4 | 0 | 23 |
| White | 24 | 5 | 21 | 24 | 20 | 12 | 4 | 20 | 12 | 24 | 23 | 3 | 19 | 3 | 214 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 3 | 2 | 0 | 0 | 0 | 0 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Jan 2021 to primary completion in Dec 2023, 34 months.
Results were first posted in Jan 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Entrectinib · Inavolisib · Alectinib · Ipatasertib · Atezolizumab · Ado-Trastuzumab Emtansine · Pertuzumab/Trastuzumab/Hyaluronidase-zzxf · Tucatinib · Paclitaxel · Tiragolumab · Pralsetinib · Trastuzumab · Pertuzumab